Chronic Lower Back Pain Market Report 2025

The chronic lower back pain market size has grown steadily in recent years. It will grow from $7.72 billion in 2024 to $8.08 billion in 2025 at a compound annual growth rate (CAGR) of 4.6%. The growth in the historic period can be attributed to sedentary lifestyles, manual labor and occupational risks, medical advancements in diagnosis, pain management evolution, epidemiological studies.

The chronic lower back pain market size is expected to see strong growth in the next few years. It will grow to $9.99 billion in 2029 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to rise in non-pharmacological interventions, preventive healthcare initiatives, focus on holistic treatments, regenerative medicine development, aging population trends. Major trends in the forecast period include focus on non-pharmacological interventions, shift in pain management approaches, healthcare awareness and education, telemedicine and remote monitoring, integration of regenerative medicine.

The chronic lower back pain market is expected to witness growth driven by an increase in the frequency of nerve instances. In this context, nerve instances refer to specific occurrences where individuals display bravery, courage, or resilience in challenging situations. Continuous exposure to stress and pain can lead to central sensitization, a phenomenon where the nervous system becomes hypersensitive, intensifying the perception of pain even in the absence of actual injury. As reported by Nature in July 2023, the prevalence of peripheral neuropathy, associated with nerve damage, is 28.4% in adults aged 40 or older with diabetes and 11.8% in those without diabetes. The rising frequency of nerve instances contributes to the growth of the chronic lower back pain market.

An increase in the geriatric population is projected to drive the growth of the chronic lower back pain market in the future. The geriatric population refers to individuals aged 65 and older. In this demographic, age-related neurodegenerative and musculoskeletal conditions, such as arthritis and osteoarthritis, tend to progress rapidly, resulting in weakness and painful complaints that contribute to chronic back pain and decreased physical activity. For example, in May 2024, the Administration for Community Living, a US-based government agency, reported that in 2022, 17.3% of the population was 65 or older. This percentage is anticipated to rise to 22% by 2040. Consequently, the growth of the geriatric population is fueling the expansion of the chronic lower back pain market.

Technological advancements emerge as a key trend gaining popularity in the chronic lower back pain market. Major companies within this market are actively involved in developing new and improved advanced technologies for the treatment and prevention of lower back pain to maintain their competitive positions. In December 2022, Abbott Laboratories, a US-based medical devices and healthcare company, introduced the Eterna spinal cord stimulation (SCS) device. Recognized as the world's smallest implantable, rechargeable spinal cord stimulator for treating chronic pain, the Eterna SCS device, featuring Abbott's low-dose BurstDR stimulation technology, has received approval from the US Food and Drug Administration (FDA). This technological innovation demonstrates the commitment of major companies to advancing the treatment options for chronic lower back pain.

Major companies in the chronic lower back pain market are actively engaged in the development of products incorporating advanced technologies, such as BurstDR SCS technology, to introduce innovative options for patients. BurstDR SCS technology is a proprietary therapy within the spinal cord stimulation (SCS) category, employing mild electrical pulses to modify pain signals during their transmission from the spinal cord to the brain. An illustration of this technological advancement is evident in the case of Abbott Laboratories, a prominent US-based medical device company. In May 2023, Abbott Laboratories received approval from the US Food and Drug Administration (FDA) for its Spinal Cord Stimulation (SCS) devices, which include the Proclaim SCS Family and Eterna SCS System specifically designed for treating chronic back pain. Abbott's SCS devices utilize the proprietary BurstDR stimulation waveform, offering a superior therapy that closely replicates the pathway of pain signals to the brain, effectively addressing the emotional aspects associated with pain. This stands in contrast to traditional tonic stimulation methods.

In November 2023, Boston Scientific, a US-based biotechnology engineering firm, acquired Relievant Medsystems, Inc. for $850 million. This acquisition strengthens Boston Scientific's portfolio in chronic pain management by integrating Relievant's Intracept intraosseous nerve ablation system, which is specifically designed to address vertebrogenic pain, a type of chronic lower back pain. Relievant Medsystems, Inc. is a US-based manufacturer of medical equipment.

Major companies operating in the chronic lower back pain market include Pfizer Inc., Johnson & Johnson Private Limited, Sanofi S.A., Endo Pharmaceuticals plc, Merck Corporation, Vertebral Technologies Inc., Medtronic plc, Boston Scientific Corporation, BioWave Corporation, Koninklijke Philips N.V., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., SpineThera Inc., Dr. Reddy's Laboratories Ltd., Celgene Corporation, Axsome Therapeutics Inc., Mesoblast Limited, Frontier Biotechnologies Inc., Eli Lilly and Company, Persica Pharmaceuticals, Abbott Laboratories, Hisamitsu Pharmaceutical Co. Inc., Ipsen S.A., Daiichi Sankyo Company Ltd., Zimmer Biomet Holdings Inc., Novartis International AG, Janssen Pharmaceuticals Inc., Insys Therapeutics Inc., Collegium Pharmaceutical Inc., Cara Therapeutics Inc.

North America was the largest region in the chronic lower back pain market in 2024. The regions covered in the chronic lower back pain market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the chronic lower back pain market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Chronic low back pain (CLBP) characterizes pain persisting for 12 weeks or more, despite treatment aimed at resolving the initial cause or acute episode of low back pain. This condition represents a major contributor to disability and often gives rise to psychological issues such as stress, depression, and anxiety.

The primary types of chronic lower back pain encompass discogenic pain, lumbar spinal stenosis, sacroiliac pain, facet-joint pain, radicular pain, muscular pain, and other variants. Discogenic pain specifically originates from damage to spinal discs, commonly associated with conditions such as degenerative disc disease, which occurs naturally as part of the aging process. Diagnosis typically involves a comprehensive clinical history, physical examination, imaging assessments, and pain evaluation. Treatment is administered across various healthcare facilities, including hospitals, orthopedic clinics, ambulatory surgery centers, among others.

The chronic lower back pain market research report is one of a series of new reports that provides chronic lower back pain market statistics, including chronic lower back pain industry global market size, regional shares, competitors with a chronic lower back pain market share, detailed chronic lower back pain market segments, market trends and opportunities, and any further data you may need to thrive in the chronic lower back pain industry. This chronic lower back pain market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The chronic low back pain market includes revenues earned by entities by providing low back pain treatment services such as pain management services, and neuropathic and nociceptive pain management. Establishments that provide long treatment plans and management services are included in this market. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.